Literature DB >> 30864049

Primary tumors of the posterior pituitary: A systematic review.

Fernando Guerrero-Pérez1, Agustina Pia Marengo2, Noemi Vidal3, Pedro Iglesias4, Carles Villabona2.   

Abstract

In 2017, the World Health Organization established that pituicytoma, granular cell tumor (GCT), spindle cell oncocytoma (SCO) and sellar ependymomas (SE) are posterior pituitary tumors (PPT). They probably arise from the pituicytes and may constitute a unique histopathological entity. We carried out a systematic review using PubMed's database. A total of 266 patients with pathological diagnosis of PPT (135 pituicytomas, 69 GCT, 47 SCO, 8 SE and 7 mixed histology tumors) were analyzed. Gender distribution was identical and median age at diagnosis was 48 ± 21.8 years. Main presentation symptoms were visual disorders (n = 142; 58.1%), headache (n = 99; 40.5%), hypopituitarism (n = 84; 34.4%), hypercortisolism (n = 10; 4.1%), polyuriapolydipsia (n = 6; 2.4%) and acromegaly features (n = 5; 2.0%). On MRI, 122 (47.6%) patients showed sellar with suprasellar extension masses, 67 (23.1%) were suprasellar and 63 (24.6%) exclusively sellar. Median tumor size was 22.0 ± 14.2 mm. Two hundred sixty four patients underwent surgery, transphenoidal access was selected in 132 (64.4%) and craniotomy in 58 (28.3%). Complications were hypopituitarism (n = 70; 42.1%), diabetes insipidus (n = 55; 33.1%) and hemorrhage (n = 50; 30.1%). Tumor persisted in 93 patients (45.6%) and recurred in 13 (6.4%). Regarding comparison between main types of PPT, SCO patients were diagnosed later (60.0 vs 47.0 vs 47.0 years, p = 0.023), the tumor was larger 25.0 mm [10.8] vs 20.0 mm [14.2] vs 2.0 mm [15.0] and they were frequently sellar with suprasellar extension tumors (71.7% vs 46.2% vs 32.8%, p = 0.003) compared to pituicytoma and GCT. In conclusion, PPT are rare tumors and have been misdiagnosed mainly as non-functioning pituitary adenomas. Different types of PPT share similar epidemiology, clinical manifestations and surgical outcomes. Surgery is the only curative option but complications and subtotal resection are common.

Entities:  

Keywords:  Granular cell tumors of the neurohypophysis; Neurohypophysis; Pituicytoma; Posterior pituitary tumors; Spindle cell oncocytoma

Mesh:

Year:  2019        PMID: 30864049     DOI: 10.1007/s11154-019-09484-1

Source DB:  PubMed          Journal:  Rev Endocr Metab Disord        ISSN: 1389-9155            Impact factor:   6.514


  154 in total

Review 1.  Benign brain tumors: sellar/parasellar tumors.

Authors:  Jay Jagannathan; Adam S Kanter; Jason P Sheehan; John A Jane; Edward R Laws
Journal:  Neurol Clin       Date:  2007-11       Impact factor: 3.806

2.  Images in clinical medicine. Hypogonadism due to pituicytoma in an identical twin.

Authors:  Harvey H Newnham; Livia M Rivera-Woll
Journal:  N Engl J Med       Date:  2008-12-25       Impact factor: 91.245

Review 3.  Granular cell tumor (choristoma) of the neurohypophysis: two cases and a review of the literature.

Authors:  L Cone; M Srinivasan; F C Romanul
Journal:  AJNR Am J Neuroradiol       Date:  1990 Mar-Apr       Impact factor: 3.825

4.  A granular-cell pituicytoma of the neurohypophysis.

Authors:  A P Massie
Journal:  J Pathol       Date:  1979-10       Impact factor: 7.996

Review 5.  Intrasellar ependymoma: clinical, imaging, pathological, and surgical findings.

Authors:  Jonathan M Parish; Jose M Bonnin; Julius M Goodman; Aaron A Cohen-Gadol
Journal:  J Clin Neurosci       Date:  2015-03-02       Impact factor: 1.961

6.  Spindle cell oncocytoma of the adenohypophysis with marked hypervascularity. Case report.

Authors:  Hironori Fujisawa; Yasuo Tohma; Naoki Muramatsu; Shinya Kida; Yasuharu Kaizaki; Hiroyasu Tamamura
Journal:  Neurol Med Chir (Tokyo)       Date:  2012       Impact factor: 1.742

7.  Non-adenomatous pituitary tumours mimicking functioning pituitary adenomas.

Authors:  Zize Feng; Zhigang Mao; Zongming Wang; Bing Liao; Yonghong Zhu; Haijun Wang
Journal:  Br J Neurosurg       Date:  2018-04-18       Impact factor: 1.596

8.  Rare infundibular tumors: clinical presentation, imaging findings, and the role of endoscopic endonasal surgery in their management.

Authors:  Maria Koutourousiou; Paul A Gardner; Julia K Kofler; Juan C Fernandez-Miranda; Carl H Snyderman; L Dade Lunsford
Journal:  J Neurol Surg B Skull Base       Date:  2012-12-31

9.  Pituicytoma (pilocytic astrocytoma). Case report.

Authors:  M L Rossi; J S Bevan; M M Esiri; J T Hughes; C B Adams
Journal:  J Neurosurg       Date:  1987-11       Impact factor: 5.115

10.  Spindle cell oncocytoma of the adenohypophysis in a woman: a case report and review of the literature.

Authors:  M Mlika; H Azouz; I Chelly; I Ben Saïd; H Jemel; S Haouet; M Zitouna; N Kchir
Journal:  J Med Case Rep       Date:  2011-02-14
View more
  13 in total

1.  Pituitary spindle cell oncocytoma: illustrative case.

Authors:  Taha M Taka; Chen Yi Yang; Joshua N Limbo; Alvin Y Chan; Jordan Davies; Edward C Kuan; Scott G Turner; Frank P K Hsu
Journal:  J Neurosurg Case Lessons       Date:  2021-10-04

2.  Recommendation to improve the WHO classification of posterior pituitary tumors as a unique entity: evidence from a large case series.

Authors:  Nidan Qiao; Haixia Cheng; Zhaoyun Zhang; Hongying Ye; Ming Shen; Xuefei Shou; Xiaoyun Cao; Hong Chen; Xiang Zhou; Yongfei Wang; Yao Zhao
Journal:  Endocr Connect       Date:  2022-06-17       Impact factor: 3.221

3.  Sellar, suprasellar, and parasellar masses: Imaging features and neurosurgical approaches.

Authors:  Bryan Lubomirsky; Zachary B Jenner; Morgan B Jude; Kiarash Shahlaie; Reza Assadsangabi; Vladimir Ivanovic
Journal:  Neuroradiol J       Date:  2021-12-02

4.  Rare neurohypophyseal tumor presenting as giant pituitary macroadenoma with cavernous sinus invasion - A case report and review of literature.

Authors:  Akhil Mohan; Prakasan Kannoth; Chandramohan Unni; Byjo Valiyaveetil Jose; Rajeev Mandaka Parambil; B N Nandeesh
Journal:  Surg Neurol Int       Date:  2020-08-29

5.  Surgical resection of granular cell tumor of the sellar region: three indications.

Authors:  Abdul-Kareem Ahmed; Hassan Y Dawood; David J Cote; Tejus A Bale; Umberto De Girolami; Edward R Laws; Timothy R Smith
Journal:  Pituitary       Date:  2019-12       Impact factor: 4.107

6.  Sellar surprises: a single-centre experience of unusual sellar masses.

Authors:  Kunal Thakkar; Swati Ramteke-Jadhav; Rajeev Kasaliwal; Saba Samad Memon; Virendra Patil; Puja Thadani; Nilesh Lomte; Shilpa Sankhe; Atul Goel; Sridhar Epari; Naina Goel; Anurag Lila; Nalini S Shah; Tushar Bandgar
Journal:  Endocr Connect       Date:  2020-02       Impact factor: 3.335

7.  Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence.

Authors:  Liza Das; Kim Vaiphei; Ashutosh Rai; Chirag Kamal Ahuja; Paramjeet Singh; Ishani Mohapatra; Rajesh Chhabra; Anil Bhansali; Bishan Dass Radotra; Ashley B Grossman; Márta Korbonits; Pinaki Dutta
Journal:  Endocr Connect       Date:  2021-04       Impact factor: 3.335

8.  Genetic and epigenetic characterization of posterior pituitary tumors.

Authors:  David Capper; M Beatriz Lopes; Simone Schmid; David A Solomon; Eilis Perez; Anne Thieme; Bette K Kleinschmidt-DeMasters; Caterina Giannini; Annekathrin Reinhardt; Sylvia L Asa; Ozgur Mete; Damian Stichel; Christin Siewert; Carsten Dittmayer; Martin Hasselblatt; Werner Paulus; Christoph Nagel; Patrick N Harter; Jens Schittenhelm; Jürgen Honegger; Elisabeth Rushing; Roland Coras; Stefan M Pfister; Rolf Buslei; Arend Koch; Arie Perry; David T W Jones; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2021-10-18       Impact factor: 17.088

9.  COL6A6 interacted with P4HA3 to suppress the growth and metastasis of pituitary adenoma via blocking PI3K-Akt pathway.

Authors:  Ruiqing Long; Zhuohui Liu; Jinghui Li; Hualin Yu
Journal:  Aging (Albany NY)       Date:  2019-10-17       Impact factor: 5.682

Review 10.  Case Report: Sellar Ependymomas: A Clinic-Pathological Study and Literature Review.

Authors:  Liyan Zhao; Yining Jiang; Yubo Wang; Yang Bai; Liping Liu; Yunqian Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-08       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.